Pfizer: ’Positive results’ emerge out of multi-drug-resistant trials
HQ Team June 1, 2023: Pfizer’s last-stage experimental trials for treating multi-drug-resistant bacteria have yielded positive results, the US-based company announced. The Phase
HQ Team May 30, 2023: Hunger is set to increase in severity and magnitude in 18 global hotspots out of 22 designated nations,
"Social interactions create a sense of community, reciprocity, and trustworthiness, which are factors positively related to mental well-being and protective against depression."
Neuralink hopes to use its microchips to treat conditions such as paralysis and blindness, and to help certain disabled people use computers and
INPEFA is an inhibitor of both sodium-glucose co-transporter type 2 (SGLT2) and type 1 (SGLT1). This class of SGLT inhibitors was recommended as